Provide are an ionic liquid composition for a carbon dioxide separation membrane, a carbon dioxide separation membrane retaining the composition in voids, and a carbon dioxide concentration apparatus provided with the carbon dioxide separation membrane that can be used to separate carbon dioxide from high partial pressure to low partial pressure. The permeability of CO.sub.2 and CO.sub.2 selectivity ratio of the carbon dioxide separation membrane can be improved, and carbon dioxide from high partial pressure to a low partial pressure of 1 kPa or lower can be selectively separated and recycled by using an ionic liquid composition prepared by combining: an ionic liquid (I) that is an aminium having one or more primary or secondary amino groups and an ethylenediamine or propylenediamine backbone in the cation; and an ionic liquid (II) in which the cation has no primary or secondary amino group and the anion is an oxoacid anion.

Provide are an ionic liquid composition for a carbon dioxide separation membrane, a carbon dioxide separation membrane retaining the composition in voids, and a carbon dioxide concentration apparatus provided with the carbon dioxide separation membrane that can be used to separate carbon dioxide from high partial pressure to low partial pressure. The permeability of CO.sub.2 and CO.sub.2 selectivity ratio of the carbon dioxide separation membrane can be improved, and carbon dioxide from high partial pressure to a low partial pressure of 1 kPa or lower can be selectively separated and recycled by using an ionic liquid composition prepared by combining: an ionic liquid (I) that is an aminium having one or more primary or secondary amino groups and an ethylenediamine or propylenediamine backbone in the cation; and an ionic liquid (II) in which the cation has no primary or secondary amino group and the anion is an oxoacid anion.

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

A benzodiazepine compound represented by formula I, or a salt thereof has an intravenous sedative anesthesia effect. The recovery quality of the compound is significantly improved compared with remimazolam in rat and mouse caudal venous anesthesia models. During anesthetization, the compound has a rapid onset, a short duration, a quick recovery and a good tolerance, can be used for anesthesia induction, anesthesia maintenance and day surgery anesthesia. ##STR00001##

The present disclosure is directed to salt forms of L-Ergothioneine and crystalline forms thereof, and processes for their preparation. Also provided is a crystalline form of L#Ergothioneine (Form C) and a crystalline form of DL-Ergothioneine (Form A).

The present disclosure is directed to salt forms of L-Ergothioneine and crystalline forms thereof, and processes for their preparation. Also provided is a crystalline form of L#Ergothioneine (Form C) and a crystalline form of DL-Ergothioneine (Form A).